[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100390753":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":58,"slug":26,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Ohio State University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Normobaric Oxygen Therapy (40% FiO2)","EXPERIMENTAL","4 weeks of nightly normobaric oxygen therapy (40% FiO2)",[13],"Device: Normobaric Oxygen",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Condition","PLACEBO_COMPARATOR","4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)",[19],"Device: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Normobaric Oxygen","40% FiO2 for 4 weeks",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","21% FiO2 for 4 weeks",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Nicholas Breitborde, PhD","CONTACT","(614) 685-6052","nicholas.breitborde@osumc.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Harding Hospital","RECRUITING","Columbus","Ohio","43210","United States",{"type":46,"coordinates":47},"Point",[48,49],-82.99879,39.96118,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":53,"phoneExt":26,"email":36},"614-685-6052",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Nicholas Breitborde","Principal Investigator","100390753",false,"NCT04368039","Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis","* Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5.\n* Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory .\n* No evidence of a pre-existing intellectual disability defined as a premorbid IQ \\>70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.\n* Ages 15-35\n* Non-smoker for past six months\n* Absence of suicidal ideation or behavior over the past month as assessed by the Columbia Suicide Severity Rating Scale\n* The American Association for Respiratory Care notes that \"no absolute contraindications to oxygen therapy exist when indications \\[for oxygen therapy\\] are present.\"","ALL","15 Years","35 Years",{"count":67,"type":68},20,"ESTIMATED","INTERVENTIONAL",[71],"NA","Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.",[74,75,76],"Psychosis","Schizophrenia","First-episode Psychosis",[78,79,80],"psychosis","treatment","normobaric hyperoxia","2026-02-23",{"date":83,"type":84},"2026-02-25","ACTUAL",{"date":86,"type":84},"2019-12-04",{"date":88,"type":68},"2026-12-07",{"name":56,"class":6},1]